Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies (Q34293555)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Sebti SM

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hamilton AD

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

6584-6593

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

A role for Rho in Ras transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Inhibition of ras prenylation: A novel approach to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Rho family proteins and Ras transformation: the RHOad less traveled gets congested.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

21 January 2018

Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204146

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1204146

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34293555&oldid=2196469731"